말 헬스케어 시장 : 제품별, 적응증별, 유통 채널별, 지역별(2026-2034년)

The global equine healthcare market size reached USD 1.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 2.7 Billion by 2034, exhibiting a growth rate (CAGR) of 5.10% during 2026-2034. The rapid increase in the equine population, rising awareness among owners regarding equine health and proper nutrition, and the utilization of advanced imaging techniques represent some of the key factors driving the market.

Equine healthcare is a branch of veterinary medicine that focuses on the diagnosis, treatment, and prevention of diseases in horses. It involves the utilization of various products, such as vaccines, dewormers, topical treatments, joint supplements, prebiotics, fly sprays, hoof conditioners, antiseptics, and performance additives. Equine healthcare includes preventive care, illness management, lameness treatment, reproductive care, oral hygiene, rehabilitation, and addressing behavioral issues. It assists in improving overall health, preventing future complications, allowing early disease detection, facilitating successful breeding, promoting a longer lifespan, and reducing the risk of serious diseases, such as lameness, dental problems, infections, obesity, herpes, and rabies.

EQUINE HEALTHCARE MARKET TRENDS:

The rapid increase in the equine population due to the widespread utilization of horses in racing, farming, and as companions is one of the primary factors propelling the market growth. Equine healthcare services and products, such as preventive care, reproductive services, rehabilitation centers, vaccines, and health supplements, are widely used to ensure optimum performance, prevent complications, protect from injuries, and reduce the risk of illnesses. In addition to this, rising awareness among the owners regarding the importance of equine health and proper nutrition is acting as another growth-inducing factor. Furthermore, the implementation of various government initiatives to support animal welfare, promote responsible ownership, and provide access to high-quality healthcare facilities is positively influencing the market growth. Additionally, the utilization of advanced imaging techniques, such as digital radiography, ultrasound, and endoscopy, to provide detailed cross-sectional images of the horse's body, thus allowing the diagnosis of musculoskeletal injuries, lameness, and internal diseases, is contributing to the market growth. Besides this, the recent development of wearable health monitoring devices for horses, which allows continuous monitoring of vital signs, activity levels, and behavior to facilitate early detection of any health issues, is providing an impetus to the market growth. Moreover, the growing number of equine sports, such as racing, jumping, dressage, and endurance riding, is propelling the market growth. Other factors, including rising expenditure capacities of consumers, emerging trends of pet humanization, extensive research and development (R&D) activities, and rapid expansion of the e-commerce industry, are anticipated to drive the market growth.

KEY MARKET SEGMENTATION:

Product Insights:

• Drugs
  • Anti-Inflammatory Drugs
  • Parasiticide Drugs
  • Others
• Vaccines
  • Live Attenuated Vaccine
  • Recombinant Vaccine
  • Others
• Medicated Feed Additives
• Diagnostics

Indication Insights:

• Musculoskeletal Disorders
• Parasite Control
• Equine Herpes Virus
• Equine Encephalomyelitis
• Equine Influenza
• West Nile Virus
• Tetanus
• Rabies

Distribution Channel Insights:

• Veterinary Hospitals and Clinics
• Retail Pharmacies and Drug Stores

Regional Insights:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for equine healthcare. Some of the factors driving the North America equine healthcare market included the rising equine population, supportive government policies, and significant technological advancements.

COMPETITIVE LANDSCAPE:

The report has also provided a comprehensive analysis of the competitive landscape in the global equine healthcare market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Boehringer Ingelheim International GmbH, Ceva, Dechra Pharmaceuticals PLC, Elanco Animal Health Incorporated, Esaote SpA, Hallmarq Veterinary Imaging, IDEXX Laboratories Inc., Merck & Co. Inc., Vetoquinol S.A., Zoetis Inc, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How has the global equine healthcare market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global equine healthcare market?
• What is the impact of each driver, restraint, and opportunity on the global equine healthcare market?
• What are the key regional markets?
• Which countries represent the most attractive equine healthcare market?
• What is the breakup of the market based on the product?
• Which is the most attractive product in the equine healthcare market?
• What is the breakup of the market based on the indication?
• Which is the most attractive indication in the equine healthcare market?
• What is the breakup of the market based on distribution channel?
• Which is the most attractive distribution channel in the equine healthcare market?
• What is the competitive structure of the global equine healthcare market?
• Who are the key players/companies in the global equine healthcare market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Equine Healthcare Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Drugs
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Anti-Inflammatory Drugs
    • 6.1.2.2 Parasiticide Drugs
    • 6.1.2.3 Others
  • 6.1.3 Market Forecast
• 6.2 Vaccines
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Live Attenuated Vaccine
    • 6.2.2.2 Recombinant Vaccine
    • 6.2.2.3 Others
  • 6.2.3 Market Forecast
• 6.3 Medicated Feed Additives
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Diagnostics
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Indication

• 7.1 Musculoskeletal Disorders
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Parasite Control
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Equine Herpes Virus
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Equine Encephalomyelitis
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Equine Influenza
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 West Nile Virus
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast
• 7.7 Tetanus
  • 7.7.1 Market Trends
  • 7.7.2 Market Forecast
• 7.8 Rabies
  • 7.8.1 Market Trends
  • 7.8.2 Market Forecast
• 7.9 Others
  • 7.9.1 Market Trends
  • 7.9.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Veterinary Hospitals and Clinics
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Retail Pharmacies and Drug Stores
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

• 10.1 Overview
• 10.2 Drivers
• 10.3 Restraints
• 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Boehringer Ingelheim International GmbH
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 SWOT Analysis
  • 14.3.2 Ceva
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 SWOT Analysis
  • 14.3.3 Dechra Pharmaceuticals PLC
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Elanco Animal Health Incorporated
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Esaote SpA
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 SWOT Analysis
  • 14.3.6 Hallmarq Veterinary Imaging
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 SWOT Analysis
  • 14.3.7 IDEXX Laboratories Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Merck & Co. Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Vetoquinol S.A.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Zoetis Inc
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis